About Us

We are looking deeper.

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. We are focused on delivering important new therapies to the millions of patients living with chronic skin conditions.

Dermira is committed to understanding and addressing the needs of both patients and physicians. We are using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology.

Our History, at a Glance

2017
  • Dermira announces positive results from CIMPACT, the final Phase 3 CIMZIA® trial in patients with moderate-to-severe chronic plaque psoriasis
2016
  • Dermira reaches a market value of $1 billion+
  • Dermira begins a Phase 3 program for olumacostat glasaretil (formerly DRM01) in patients with acne vulgaris
  • Dermira announces positive topline results from CIMPASI-1 and CIMPASI-2, the first two trials from the Phase 3 clinical program evaluating CIMZIA as a potential treatment option for patients with moderate-to-severe chronic plaque psoriasis
  • Dermira raises $136 million through a follow-on equity financing
  • Dermira announces positive topline results from the Phase 3 clinical program evaluating glycopyrronium tosylate (formerly DRM04) as a potential treatment option for patients with primary axillary hyperhidrosis
  • Dermira announces topline results from the Phase 2b program evaluating olumacostat glasaretil in patients with acne vulgaris
2015
  • Dermira raises $104 million through a follow-on equity financing
  • Dermira begins a Phase 3 program for glycopyrronium tosylate in patients with primary axillary hyperhidrosis
  • Dermira begins a Phase 2b program for olumacostat glasaretil in patients with acne vulgaris
2014
  • Dermira begins a Phase 3 program for CIMZIA in patients with moderate-to-severe chronic plaque psoriasis
  • Dermira goes public, raising $113 million, and is listed on NASDAQ as DERM
  • Dermira raises $49 million in a Series C financing from existing investors and new healthcare-focused funds
  • Dermira enters into a collaboration agreement with UCB S.A. to develop and commercialize CIMZIA as a treatment for patients with moderate-to-severe chronic plaque psoriasis
2013
  • Dermira raises $35 million in a Series B financing with investments from Osaka-based Maruho Co., Ltd., a leading dermatology company in Japan, and existing investors Bay City Capital, New Enterprise Associates and Canaan Partners
2012
  • Dermira initiates hyperhidrosis development program
2011
  • Dermira raises $34 million in a Series A financing with investments from Bay City Capital, New Enterprise Associates and Canaan Partners
  • Dermira acquires olumacostat glasaretil, a topical product candidate as a potential treatment for acne vulgaris
2010
  • Dermira is founded in Redwood City, Calif., with $1 million in funding from Bay City Capital